OBJECTIVE： To compare therapecttic efficacy and safety of rosuvastation for patients with acute cerebral infarction （ACI） before and after the application of intravenous thrombolysis. METHODS： A total of 90 ACI patients receiving intravenous thrombolysis selected from Hainan Provincial People’s Hospital during Jan. 2014-Oct. 2016 were divided into pre-thrombolytic group （45 cases） and post-thrombolytic group （45 cases） according to random number table. Both were given rosuvastation （10 mg，qd） orally within 24 h before and after intravenous thrombolysis for 8 weeks. The rate of excellent prognosis were compared between 2 groups， and NIHSS score， ADL-Barthel index score， the levels of laboratory indexes （HMGB1， MMP-9， IL-17）， the incidence of intracranial hemorrhage and the occurrence of ADR were compared before and after treatment. RESULTS： The rate of excellent prognosis in pre-thrombolytic group one and eight weeks after thrombolysis was significantly higher than post-thrombolytic group. NIHSS score， ADL-Barthel index score， the levels of HMGB1， MMP-9 and IL-17 in 2 groups after treatment were significantly better than before treatment； the pre-thrombolytic group were significantly better than the post-thrombolytic group， with statistical significance （P＜0.05）. There was no significant difference in the incidence of intracranial hemorrhage between 2 groups（P＞0.05）， and no obvious ADR was found. CONCLUSIONS： Compared with post-thrombolytic medication， rosuvastation used before intravenous thrombolysis can significantly improve long-term prognosis， promote the recovery of neurological function and quality of daily life and reduce the levels of HMGB1， MMP-9 and IL-17， but does not increase the risk of intracranial hemorrhage with good safety.